Adverse outcome post acute coronary syndrome in diabetes

Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes post-acute coronary syndrome in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN10805074

Enrollment

420

Registered

2017-01-20

Start date

2012-06-15

Completion date

Unknown

Last updated

2017-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Acute coronary syndrome 2. Type-2 diabetes mellitus (T2DM) Circulatory System 1. Acute coronary syndrome 2. Type-2 diabetes mellitus (T2DM)

Interventions

All study participants are enrolled into the study during their ACS hospitalization. During hosptialisation, participants are treated using standard techniques. This may include percutaneous coronary

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Confirmed acute coronary syndrome 2. Has PAPP-A measurements

Exclusion criteria

Exclusion criteria: 1. Aystemic inflammatory disease or cancer 2. Missing PAPP-A measurements

Design outcomes

Primary

Measure	Time frame
1. Cardiovascular death rate is assessed by medical record review and confirmed with death certificate at baseline, 6, 12 and 24 months of the 2 years of follow-up 2. Non-fatal MI rate is assessed by patient interview and confirmed by medical record review at baseline, 6, 12 and 24 months of the 2 years of follow-up 3. Non-fatal stroke rate is assessed by patient interview and confirmed by medical record review at baseline, 6, 12 and 24 months of the 2 years of follow-up	—

Measure

Time frame

1. Cardiovascular death rate is assessed by medical record review and confirmed with death certificate at baseline, 6, 12 and 24 months of the 2 years of follow-up 2. Non-fatal MI rate is assessed by patient interview and confirmed by medical record review at baseline, 6, 12 and 24 months of the 2 years of follow-up 3. Non-fatal stroke rate is assessed by patient interview and confirmed by medical record review at baseline, 6, 12 and 24 months of the 2 years of follow-up

—

Secondary

Measure	Time frame
No secondary outcome measures.	—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 10, 2026